The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 4, 2012, Pages 991-997

  Bello, Carlo L ^a   LaBadie, Robert R ^a   Ni, Grace ^a   Boutros, Tanya ^a   McCormick, Carol ^a   Ndongo, M Noella ^a  

^a PFIZER INC   (United States)

Author keywords

CYP2D6 extensive metabolizers; Dacomitinib; Dextromethorphan; Drug drug interaction (DDI); Healthy volunteers; PF 00299804

Indexed keywords

CYTOCHROME P450 2D6; DACOMITINIB; DEXTROMETHORPHAN; DEXTRORPHAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; ENZYME ACTIVITY; ENZYME METABOLISM; FEMALE; FLATULENCE; HEADACHE; HEMORRHOID; HUMAN; HUMAN EXPERIMENT; INTESTINE SOUND; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; WOUND;

ADULT; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DRUG INTERACTIONS; HUMANS; MALE; QUINAZOLINONES;

EID: 84859803776     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1793-7     Document Type: Article

References (33)

1. Engelman JA, Zejnullahu K, Gale C-M et al (2007) PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67(24):11924-11932
2. Gonzales AJ, Hook KE, Althaus IW et al (2008) Antitumor activity and pharmacokinetic properties of PF-00299804, a second- generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 7(7):1880-1889
3. Jänne PA, Boss DS, Camidge DR et al (2011) Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 17:1131-1139
4. Janne PA, Reckamp KL, Koczywas M (2009) Efficacy and safety of PF-00299804 in patients with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib: a two-arm, phase II trial. J Clin Oncol 27(15S):abstr 8063
5. Janne PA, Schellens JH, Engelman JA et al (2008) Preliminary activity and safety results from a phase I clinical trial of PF- 00299804, an irreversible pan-HER inhibitor, in patients with NSCLC. J Clin Oncol 26(15S):abstr 8027
6. Boyer MJ, Blackhall FH, Park K et al (2010) Efficacy and safety of PF299804 versus erlotinib: a global, randomized phase II trial in patients with advanced non-small cell lung cancer after failure of chemotherapy. J Clin Oncol 28(18S):abstr LBA7523
7. Mok T, Spigel DR, Park K et al (2010) Efficacy and safety of PF- 00299804, an oral, irreversible, pan-human epidermal growth factor receptor tyrosine kinase inhibitor, as first-line treatment of selected patients with advanced non-small cell lung cancer. J Clin Oncol 28(15S):abstr 7537
8. Park K, Heo DS, Cho BC et al (2010) PF-00299804 in Asian patients with non-small cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II study. J Clin Oncol 28(15S):abstr 7599
9. Ramalingam SS, Boyer MJ, Park K et al (2010) Randomized phase 2 study of PF-00299804, an irreversible human epidermal growth factor inhibitor, versus erlotinib in patients with advanced non-small cell lung cancer after chemotherapy failure: quantitative and qualitative benefits. Annals Oncol 21(Suppl 8):abstr 365PD
10. Le Tourneau C, Winquist E, Hotte SJ et al (2010) Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 as first-line treatment in recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 28(15S):abstr 5531
11. Bertilsson L, Dahl ML, Dalén P, Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53(2):111-122 (Pubitemid 34264265)
12. Frank D, Jaehde U, Fuhr U (2007) Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 63(4):321-333 (Pubitemid 46399125)
13. De Gregori M, Allegri M, De Gregori S et al (2010) How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments. Curr Drug Metab 11:276-282
14. Zhou SF (2009) Polymorphism of human cytochrome P450 2D6, its clinical significance: part I. Clin Pharmacokinet 48(11): 689-723
15. Neafsey P, Ginsberg G, Hattis D, Sonawane B (2009) Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev 12(5-6):334-361
16. Chen S, Chou W-H, Blouin RA et al (1996) The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism. Screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 60:522-534 (Pubitemid 26414088)
17. Chou WH, Yan F-X, de Leon J et al (2000) Extension of a pilot study: impact of the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 20:246-251 (Pubitemid 30202369)
18. Wojtczak A, Rychlik-Sych M, Krochmalska-Ulacha E, Skretkowicz J (2007) CYP2D6 phenotyping with dextromethorphan. Pharmacol Rep 59(6):734-738 (Pubitemid 351586566)
19. US Food and Drug Administration. Draft Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling (2006). Available at: http:// www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/ucm072101.pdf
20. Rodríguez-Antona C, Jover R, Gómez-Lechón MJ, Castell JV (2000) Quantitative RT-PCR measurement of human cytochrome P-450 s: application to drug induction studies. Arch Biochem Biophys 376(1):109-116
21. Edwards RJ, Price RJ, Watts PS et al (2003) Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 31(3):282-288 (Pubitemid 36249682)
22. Feidt DM, Klein K, Hofmann U et al (2010) Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes. Drug Metab Dispos 38(9):1589-1597
23. Fux R, Mörike K, Pröhmer AM et al (2005) Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 78(4):378-387 (Pubitemid 41393673)
24. Sachse C, Brockmoller J, Bauer S et al (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295 (Pubitemid 27058401)
25. Bertilsson L, Lou YQ, Du YL et al (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 51:388-397
26. Alván G, Bechtel P, Iselius L et al (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39:533-537
27. Eichelbaum M, Gross AS (1992) The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon Press Inc, New York, pp 625-648
28. Nakamura K, Goto F, Ray WA et al (1985) Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol 38:402-408 (Pubitemid 16250313)
29. Sohn D-R, Shin S-G, Park C-W et al (1991) Metoprolol oxidation polymorphism in a Korean population. Comparison with native Japanese and Chinese populations. Br J Clin Pharmacol 32:504-507
30. Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 48(12):761-804
31. Beverage JN, Sissung TM, Sion AM et al (2007) CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci 96(9):2224-2231 (Pubitemid 47477881)
32. Goetz MP, Kamal A, Ames AA et al (2008) Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 83:160-166
33. Lessard E, Yessine MA, Hamelin BA et al (2001) Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol 21:175-184 (Pubitemid 32221055)